Biosimilar Antibodies

Ibritumomab Biosimilar – Anti-MS4A1(CD20,MS4A-1) mAb – Research Grade, ProteoGenix, PX-TA1620

Description of Ibritumomab Biosimilar - Anti-MS4A1(CD20,MS4A-1) mAb - Research Grade Title: Understanding the Structure and Function of Ibritumomab Biosimilar – Anti-MS4A1(CD20,MS4A-1) mAb Introduction: Ibritumomab Biosimilar is a monoclonal antibody (mAb) that targets the protein MS4A1, also known as CD20, on the surface of B cells. It is a biosimilar of the original drug ibritumomab tiuxetan, which is used for the treatment of non-Hodgkin’s lymphoma. In this article, we will delve into the structure, activity, and potential applications of Ibritumomab Biosimilar as a research grade antibody. Structure of Ibritumomab Biosimilar: Ibritumomab Biosimilar is a recombinant, chimeric monoclonal antibody, meaning it is produced by combining genetic material from two different species – human and mouse. It consists of two heavy chains and two light chains, each with a specific amino acid sequence that determines its structure and function. The heavy chains are responsible for binding to the target protein, MS4A1, while the light chains provide support and stability to the antibody. Activity of Ibritumomab Biosimilar: As a monoclonal antibody, Ibritumomab Biosimilar specifically targets and binds to the protein MS4A1 on the surface of B cells. This binding triggers a series of events that ultimately leads to the destruction of the B cell. The antibody recruits immune cells, such as natural killer cells and macrophages, to the site of the bound B cell and activates them to attack and destroy the cell. This mechanism of action is known as antibody-dependent cell-mediated cytotoxicity (ADCC). Applications of Ibritumomab Biosimilar: Ibritumomab Biosimilar, as a research grade antibody, has several potential applications in the field of immunology and cancer research. Its primary use is in the study of B cell biology and the role of MS4A1 in B cell function. By targeting and depleting B cells, researchers can investigate the effects of B cell deficiency on the immune system. This can also aid in the development of new therapies for B cell-related diseases. Moreover, Ibritumomab Biosimilar can also be used in the development of new cancer treatments. The overexpression of MS4A1 has been observed in various types of B cell lymphomas, making it a potential therapeutic target. By targeting and destroying MS4A1-expressing B cells, Ibritumomab Biosimilar can potentially be used as a treatment for these types of cancers. In addition, Ibritumomab Biosimilar can also be used in diagnostic assays for B cell-related diseases. The specificity of the antibody for MS4A1 allows for the detection and quantification of B cells in patient samples. This can aid in the diagnosis and monitoring of diseases such as B cell lymphomas and autoimmune disorders. Conclusion: In conclusion, Ibritumomab Biosimilar is a chimeric monoclonal antibody that specifically targets the protein MS4A1 on B cells. Its structure and activity make it a valuable tool for studying B cell biology and the development of new cancer treatments. As a research grade antibody, it has the potential for various applications in the fields of immunology and cancer research. Further studies and developments in this area can lead to the advancement of new therapies and diagnostic tools for B cell-related diseases.

Icrucumab Biosimilar – Anti-FLT1, VEGFR-1 mAb – Research Grade, ProteoGenix, PX-TA1257

Description of Icrucumab Biosimilar - Anti-FLT1, VEGFR-1 mAb - Research Grade General information on Anti-FLT1/ VEGFR-1[Homo sapiens] (Icrucumab) Monoclonal Antibody Icrucumab is investigated for the treatment of Colorectal Cancer.

Ieramilimab Biosimilar – Anti-LAG3 mAb – Research Grade, ProteoGenix, PX-TA1562

Description of Ieramilimab Biosimilar - Anti-LAG3 mAb - Research Grade Introduction: Ieramilimab Biosimilar, also known as Anti-LAG3 mAb, is a research grade monoclonal antibody that has shown promising results in pre-clinical studies as a potential therapeutic target for various diseases. This article will provide a detailed description of the structure, activity, and potential applications of Ieramilimab Biosimilar in the field of immunotherapy. Structure of Ieramilimab Biosimilar: Ieramilimab Biosimilar is a humanized monoclonal antibody that targets the lymphocyte activation gene 3 (LAG3) protein. It is composed of two identical heavy chains and two identical light chains, each containing a variable and constant region. The variable region of the antibody is responsible for binding to the LAG3 protein, while the constant region determines the effector function of the antibody. Activity of Ieramilimab Biosimilar: LAG3 is a cell surface protein that is primarily expressed on activated T cells and natural killer (NK) cells. It plays a crucial role in regulating immune responses by inhibiting the activation and proliferation of T cells. However, in certain diseases, such as cancer and autoimmune disorders, LAG3 expression is upregulated, leading to immune suppression and disease progression. Ieramilimab Biosimilar works by binding to LAG3 and blocking its inhibitory function, thereby promoting immune responses against cancer cells or reducing autoimmunity. Potential Applications of Ieramilimab Biosimilar: 1. Cancer Immunotherapy: One of the most promising applications of Ieramilimab Biosimilar is in the field of cancer immunotherapy. By targeting LAG3, this antibody can enhance the anti-tumor immune response and potentially improve the efficacy of other cancer therapies. Pre-clinical studies have shown that Ieramilimab Biosimilar can inhibit tumor growth and improve survival rates in various cancer models, including melanoma, lung cancer, and breast cancer. 2. Autoimmune Disorders: Autoimmune disorders, such as rheumatoid arthritis and multiple sclerosis, are characterized by an overactive immune response against the body’s own tissues. LAG3 is known to play a role in the development and progression of these diseases. By blocking LAG3, Ieramilimab Biosimilar can potentially reduce the activity of autoreactive T cells and alleviate symptoms of autoimmune disorders. 3. Infectious Diseases: LAG3 has also been implicated in the immune response against certain infectious diseases, such as HIV and tuberculosis. Pre-clinical studies have shown that Ieramilimab Biosimilar can enhance the immune response against these pathogens and potentially improve the efficacy of current treatments. 4. Combination Therapy: Due to its unique mechanism of action, Ieramilimab Biosimilar has the potential to be used in combination with other immunotherapies, such as checkpoint inhibitors and CAR T cell therapy. This combination approach can potentially enhance the anti-tumor immune response and improve treatment outcomes for cancer patients. Conclusion: In conclusion, Ieramilimab Biosimilar is a promising research grade monoclonal antibody that targets LAG3 and has shown potential in the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Its unique mechanism of action and potential for combination therapy make it an exciting candidate for further development in the field of immunotherapy. Further clinical studies are needed to fully explore the potential of Ieramilimab Biosimilar and its role in the treatment of these diseases.

Ifinatamab Biosimilar – Anti-CD276 mAb – Research Grade, ProteoGenix, PX-TA1847

Description of Ifinatamab Biosimilar - Anti-CD276 mAb - Research Grade Introduction Ifinatamab Biosimilar, also known as Anti-CD276 mAb, is a research grade monoclonal antibody that has shown promising results in the treatment of various cancers. This antibody specifically targets the CD276 protein, which is overexpressed in many types of cancer cells. In this article, we will delve into the structure, activity, and potential applications of Ifinatamab Biosimilar. Structure of Ifinatamab Biosimilar Ifinatamab Biosimilar is a monoclonal antibody, meaning it is derived from a single type of immune cell. It is a fully humanized antibody, meaning it is made up of human proteins and is less likely to cause an immune response in patients. The antibody is composed of two identical heavy chains and two identical light chains, which are connected by disulfide bonds. These chains form the Y-shaped structure commonly seen in antibodies. The variable regions of Ifinatamab Biosimilar are responsible for its specificity towards the CD276 protein. These regions, also known as the antigen-binding regions, are located at the tips of the Y-shaped structure and are highly variable between different antibodies. The constant regions of the antibody are responsible for its effector functions, such as binding to immune cells and activating them to attack cancer cells. Activity of Ifinatamab Biosimilar The primary activity of Ifinatamab Biosimilar is its ability to bind to the CD276 protein. CD276, also known as B7-H3, is a cell surface protein that is overexpressed in many types of cancer cells. This protein plays a role in promoting cancer cell growth and survival, making it an attractive target for cancer treatment. When Ifinatamab Biosimilar binds to CD276, it blocks its activity and prevents it from promoting cancer cell growth. This can lead to the death of cancer cells and inhibit tumor growth. Additionally, the binding of Ifinatamab Biosimilar to CD276 can also activate the immune system to attack cancer cells, further enhancing its anti- cancer activity. Applications of Ifinatamab Biosimilar The primary application of Ifinatamab Biosimilar is in the treatment of cancer. It has shown promising results in preclinical studies and is currently being evaluated in clinical trials for various types of cancer, including lung cancer, breast cancer, and ovarian cancer. The ability of Ifinatamab Biosimilar to specifically target CD276 makes it a potentially effective and safe treatment option for these cancers. Furthermore, Ifinatamab Biosimilar may also have potential applications in immunotherapy. By activating the immune system to attack cancer cells, it can be used in combination with other immunotherapies to enhance their efficacy. This could potentially lead to more effective and personalized treatments for cancer patients. Conclusion Ifinatamab Biosimilar, also known as Anti-CD276 mAb, is a research grade monoclonal antibody that specifically targets the CD276 protein. Its structure, activity, and potential applications make it a promising candidate for the treatment of various types of cancer. As research and clinical trials continue, Ifinatamab Biosimilar may play a crucial role in improving outcomes for cancer patients and advancing the field of cancer treatment.

Imalumab Biosimilar – Anti-MIF mAb – Research Grade, ProteoGenix, PX-TA1359

Description of Imalumab Biosimilar - Anti-MIF mAb - Research Grade General information on Anti-MIF[Homo sapiens] (Imalumab) Monoclonal Antibody Imalumab is investigatedfor the treatment of Malignant Ascites of Ovarian Cancer.

Imsidolimab Biosimilar – Anti-IL36R mAb – Research Grade, ProteoGenix, PX-TA1674

Description of Imsidolimab Biosimilar - Anti-IL36R mAb - Research Grade Introduction Imsidolimab Biosimilar, also known as Anti-IL36R mAb, is a monoclonal antibody that targets the interleukin-36 receptor (IL-36R). This therapeutic antibody has shown promising results in pre-clinical and clinical studies for the treatment of various inflammatory and autoimmune diseases. In this article, we will delve into the structure, activity, and potential applications of Imsidolimab Biosimilar. Structure of Imsidolimab Biosimilar Imsidolimab Biosimilar is a fully humanized monoclonal antibody that is produced using recombinant DNA technology. It is composed of two heavy chains and two light chains, each with a molecular weight of approximately 25 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab region is responsible for binding to the IL-36R, while the Fc region is involved in effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). Activity of Imsidolimab Biosimilar Imsidolimab Biosimilar specifically targets the IL-36R, which is a receptor expressed on the surface of various immune cells, including T cells, dendritic cells, and macrophages. IL-36R is a member of the interleukin-1 (IL-1) receptor family and is involved in the regulation of inflammatory responses. When activated by its ligands, IL-36R triggers a cascade of signaling pathways that lead to the production of pro-inflammatory cytokines, such as interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). By binding to the IL-36R, Imsidolimab Biosimilar blocks the interaction between the receptor and its ligands, thereby inhibiting the downstream signaling pathways and reducing the production of pro-inflammatory cytokines. This mechanism of action makes Imsidolimab Biosimilar a potent anti-inflammatory agent. Potential Applications of Imsidolimab Biosimilar Imsidolimab Biosimilar has shown promising results in pre-clinical and clinical studies for the treatment of various inflammatory and autoimmune diseases, including psoriasis, psoriatic arthritis, and hidradenitis suppurativa. These diseases are characterized by an overactive immune response, leading to chronic inflammation and tissue damage. In a phase II clinical trial, Imsidolimab Biosimilar demonstrated significant efficacy in reducing the severity of psoriasis symptoms, such as skin lesions and itching, compared to placebo. The antibody also showed a favorable safety profile, with no serious adverse events reported. These results suggest that Imsidolimab Biosimilar could be a potential treatment option for patients with moderate to severe psoriasis. Another potential application of Imsidolimab Biosimilar is in the treatment of psoriatic arthritis, a chronic inflammatory disease that affects the joints. In a phase II clinical trial, Imsidolimab Biosimilar showed significant improvement in joint symptoms, such as pain and swelling, in patients with psoriatic arthritis. The antibody also demonstrated a good safety profile, with no serious adverse events reported. In addition to psoriasis and psoriatic arthritis, Imsidolimab Biosimilar has also shown promising results in the treatment of hidradenitis suppurativa, a chronic inflammatory skin disease. In a phase II clinical trial, the antibody significantly reduced the number of skin lesions and improved the quality of life in patients with hidradenitis suppurativa. The safety profile of Imsidolimab Biosimilar was also favorable, with no serious adverse events reported. Conclusion In summary, Imsidolimab Biosimilar is a promising therapeutic antibody that specifically targets the IL-36R and has shown significant efficacy in pre-clinical and clinical studies for the treatment of various inflammatory and autoimmune diseases. Its unique mechanism of action and favorable safety profile make it a potential treatment option for patients with psoriasis

Inclacumab Biosimilar – Anti-SELP mAb – Research Grade, ProteoGenix, PX-TA1279

Description of Inclacumab Biosimilar - Anti-SELP mAb - Research Grade General information on Anti-SELP[Homo sapiens] (Inclacumab) Monoclonal Antibody Inclacumab has investigated for the treatment and prevention of Myocardial Infarction, Peripheral Arterial Disease (PAD), and Coronary Heart Disease.

Inclocibart Biosimilar – Research Grade, ProteoGenix, PX-TA2485-100

Inebilizumab Biosimilar – Anti-CD19 mAb – Research Grade, ProteoGenix, PX-TA1385

Description of Inebilizumab Biosimilar - Anti-CD19 mAb - Research Grade General information on Anti-CD19[Homo sapiens] (Inebilizumab) Monoclonal Antibody Inebilizumab is a humanized afucosylated monoclonal IgG1 antibody that targets the broadly expressed B-cell surface antigen CD19. Inebilizumab is cytolytic, which may be usefull to treat neuromyelitis optica spectrum disorder (NMOSD)through B-cell depletion.

Infliximab Biosimilar – Anti-TNF-alpha mAb – Research Grade, ProteoGenix, PX-TA1009

Description of Infliximab Biosimilar - Anti-TNF-alpha mAb - Research Grade General information about Infliximab Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases. This includes Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet’s disease. It is given by slow injection into a vein, typically at six- to eight-week intervals. Infliximab was originally developed in mice as a mouse antibody. Because humans have immune reactions to mouse proteins, the mouse common domains were replaced with similar human antibody domains. They are monoclonal antibodies and have identical structures and affinities to the target. Because they are a combination of mouse and human antibody amino acid sequences, they are called a “chimeric monoclonal antibody”. This product is for research use only.